Bio-Bridge Science (BGES.OB) Listed On OTC BB

Bio-Bridge Science, an Oak Brook Illinois-based biotech
company, announced today that its shares are now listed on the
Over-the-Counter Bulletin Board under the ticker symbol "BGES".
   "We are very pleased to see our stock listed on the electronic
bulletin board", said Chairman and CEO Liang Qiao. "Our company is
engaged in cutting-edge research in a vitally important field of
medicine. Our unique technology and our presence on the ground in
China, where AIDS infection rates are spiraling upwards, puts us at
the forefront of the fight against the global AIDS pandemic. Our
listing on a U.S. exchange will enable us to more effectively
communicate our progress to investors."
   Bio-Bridge Science is a biotechnology firm focused on the
development of vaccines with broad therapeutic and preventive
applications. Through its wholly owned subsidiary in Beijing,
Bio-Bridge is developing a promising new HIV Vaccine, that is expected
to enter clinical trials early next year in China. The vaccine, based
on exclusive technology co-developed by CEO Liang Qiao, an associate
professor at Loyola University Chicago's Strich School of Medicine,
targets infection in mucosal tissues, the first type of tissue
attacked by HIV.
   The Chinese government, mindful of the rapid expansion of AIDS in
China has, through the "Green Mile Policy" acted to expedite the
approval of domestically produced HIV Vaccines and has dramatically
increased its spending on AIDS-related research. In accordance with
this policy, Bio-Bridge expects to bring its therapeutic HIV Vaccine
to market as early as 2008, far in advance of many other HIV Vaccines
currently in development. Bio-Bridge is currently constructing a new
$3 million state-of-the-art GMP research and manufacturing facility in
Beijing, which is expected to be completed by the end of this year.